I agree that what you've stated about the crowded HCV market in general makes my theory unlikely. If ACHN does end up doing a raise within the next few days that would make it a pump and do more harm than good for mgmt's reputation. As a small biotech I'm not sure they want that reputation.
Market Data 
Markets 
AI
